Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00321490 · ClinicalTrials.gov registry record · Phase 3
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
NCT00321490 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 600 participants.
The verdict
NCT00321490, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
Study Summary
This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.
Interventions
- DRUG Duloxetine
- DRUG Quetiapine fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2006-04 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00321490
The ClinicalTrials.gov registry entry for NCT00321490 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Duloxetine is the first listed.
NCT00321490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00321490 about?
NCT00321490 is a clinical study titled "Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder". This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.
What is the current status of trial NCT00321490?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2006-04. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00321490?
The interventions under investigation include: Duloxetine (DRUG), Quetiapine fumarate (DRUG).
Who is sponsoring clinical trial NCT00321490?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.